These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23795818)
21. A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Zeng W; Azzopardi K; Hocking D; Wong CY; Robevska G; Tauschek M; Robins-Browne RM; Jackson DC Vaccine; 2012 Jul; 30(32):4800-6. PubMed ID: 22634295 [TBL] [Abstract][Full Text] [Related]
22. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population. Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096 [TBL] [Abstract][Full Text] [Related]
23. The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity. Toussi DN; Liu X; Massari P Clin Vaccine Immunol; 2012 Jul; 19(7):1093-101. PubMed ID: 22623652 [TBL] [Abstract][Full Text] [Related]
24. Simple synthetic toll-like receptor 2 ligands. Abdel-Aal AB; Al-Isae K; Zaman M; Toth I Bioorg Med Chem Lett; 2011 Oct; 21(19):5863-5. PubMed ID: 21855334 [TBL] [Abstract][Full Text] [Related]
25. Avian influenza virus vaccines containing Toll-like receptors 2 and 5 ligand adjuvants promote protective immune responses in chickens. St Paul M; Brisbin JT; Barjesteh N; Villaneueva AI; Parvizi P; Read LR; Nagy E; Sharif S Viral Immunol; 2014 May; 27(4):160-6. PubMed ID: 24797722 [TBL] [Abstract][Full Text] [Related]
26. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands. Xu Z; Moyle PM Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637 [TBL] [Abstract][Full Text] [Related]
27. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. Wu W; Li R; Malladi SS; Warshakoon HJ; Kimbrell MR; Amolins MW; Ukani R; Datta A; David SA J Med Chem; 2010 Apr; 53(8):3198-213. PubMed ID: 20302301 [TBL] [Abstract][Full Text] [Related]
29. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2). Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965 [TBL] [Abstract][Full Text] [Related]
31. Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. Christiansen D; Earnest-Silveira L; Chua B; Boo I; Drummer HE; Grubor-Bauk B; Gowans EJ; Jackson DC; Torresi J Viral Immunol; 2018 May; 31(4):338-343. PubMed ID: 29489437 [TBL] [Abstract][Full Text] [Related]
32. Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity. Wijayadikusumah AR; Sullivan LC; Jackson DC; Chua BY Amino Acids; 2017 Oct; 49(10):1691-1704. PubMed ID: 28718065 [TBL] [Abstract][Full Text] [Related]
33. Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam Du X; Qian J; Wang Y; Zhang M; Chu Y; Li Y Bioorg Med Chem; 2019 Jul; 27(13):2784-2800. PubMed ID: 31101493 [TBL] [Abstract][Full Text] [Related]
34. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Chua BY; Olson MR; Bedoui S; Sekiya T; Wong CY; Turner SJ; Jackson DC Immunol Cell Biol; 2014 Apr; 92(4):377-83. PubMed ID: 24394993 [TBL] [Abstract][Full Text] [Related]
35. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. Chua BY; Pejoski D; Turner SJ; Zeng W; Jackson DC J Immunol; 2011 Aug; 187(4):1692-701. PubMed ID: 21742967 [TBL] [Abstract][Full Text] [Related]
36. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Cataldi A; Yevsa T; Vilte DA; Schulze K; Castro-Parodi M; Larzábal M; Ibarra C; Mercado EC; Guzmán CA Vaccine; 2008 Oct; 26(44):5662-7. PubMed ID: 18675866 [TBL] [Abstract][Full Text] [Related]
38. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Roth A; Espuelas S; Thumann C; Frisch B; Schuber F Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182 [TBL] [Abstract][Full Text] [Related]
39. Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice. Laiño J; Wangorsch A; Blanco F; Wolfheimer S; Krause M; Flaczyk A; Möller TM; Tsai M; Galli S; Vieths S; Toda M; Scheurer S; Schülke S J Immunol Res; 2017; 2017():7983217. PubMed ID: 29204451 [TBL] [Abstract][Full Text] [Related]
40. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]